Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s stock price traded down 0.7% during mid-day trading on Monday . The company traded as low as C$6.04 and last traded at C$6.09. 82,521 shares were traded during trading, an increase of 25% from the average session volume of 66,027 shares. The stock had previously closed at C$6.13.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the company. Canaccord Genuity Group set a C$6.50 target price on Knight Therapeutics and gave the company a "buy" rating in a research report on Friday, May 9th. Stifel Nicolaus increased their target price on Knight Therapeutics from C$6.25 to C$7.45 and gave the company a "buy" rating in a research report on Tuesday, March 25th. Two equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Strong Buy" and an average price target of C$7.15.
Get Our Latest Stock Analysis on Knight Therapeutics
Knight Therapeutics Trading Down 0.7%
The company has a 50 day moving average of C$5.90 and a 200 day moving average of C$5.77. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The stock has a market capitalization of C$616.00 million, a price-to-earnings ratio of -20.33, a P/E/G ratio of -1,013.50 and a beta of 0.50.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
